The MGISP-Smart 8, a groundbreaking lab automation platform, was unveiled to great acclaim at MEDICA. This dynamic system, equipped with an 8-channel independent pipetting robot, delivers exceptional lab automation versatility. Whether for sequencing library preparation, nucleic acid detection, or sample preparation, MGISP-Smart 8 is an optimal choice for a wide array of applications.

Bearing a suite of advanced technologies like the intelligent integrated gripper and triple slide track design, the MGISP-Smart 8 enables efficient and precise operations. It stands out with its independent multi-channel dynamic positioning and dual-level liquid detection, enhancing the reliability and accuracy of sample handling. This system empowers genomics researchers and clinicians to achieve remarkable results and progress in their work.

At MEDICA, we are not only introducing the MGISP-Smart 8, but also presenting a wide range of products from our extensive portfolio. Visitors will have the opportunity to explore two other automated sample preparation systems, the MGISP-100 and MGISP-960, as well as the DNBSEQ-G400 genetic sequencer. These cutting-edge devices reflect our commitment to providing high-quality tools that drive advancements in life science research and clinical applications.

Additionally, we are thrilled to have representatives from MGI IMABOT joining us at the event to demonstrate the robotic ultrasound system, MGIUS-R3. This state-of-the-art technology showcases our dedication to integrating innovative solutions across multiple domains of healthcare.

The launch of our Empowerment Program coincided with this year's MEDICA event. This program is a testament to our commitment to fostering collaboration with diagnostic companies and public institutions. The aim is to develop library preparation kits that are fully compatible with MGI sequencing platforms, thereby accelerating the IVDR certification process and providing more choices in the sequencing field.

The Empowerment Program grants participating companies access to our proprietary DNBSEQ™ technology, featuring MGI's HotMPS chemistry. This technology has catalyzed breakthroughs in areas such as oncology and reproductive health. By extending this opportunity to our partners, we strive to make a significant collective impact on patient care and health outcomes.

At MGI, we champion the potential of genomics. By sharing our expertise and technical resources, we enable more companies and institutions to seamlessly leverage our DNBSEQ™ platforms. Through collaboration, we aim to empower researchers and clinicians in their pursuit of advancing health and well-being for all.

We have fostered successful collaborations with notable technology platforms, such as VarSome in Switzerland and ALACRiS Theranostics in Germany. These partnerships have enabled us to offer expert solutions for high-throughput sequencing users and comprehensive end-to-end solutions for cancer diagnostics. Through the Empowerment Program, we aim to extend our support to more organizations across Europe.

MEDICA was a wonderful opportunity for our valued customers, distributors, and partners to explore our high-quality sequomics. We thank everyone who joined us in this pivotal event and look forward to future opportunities to showcase our commitment to advancing genomics and providing innovative solutions to pressing health challenges. Our presence at MEDICA allowed us to build strong relationships, gain valuable feedback, and learn more about the needs of the healthcare community. We are excited about the potential these connections hold for the future of genomics and the meaningful impact our technologies can have on patient care. We are grateful to MEDICA for the platform and to all attendees for the engaging discussions.

 

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit MGI website or connect on Twitter, LinkedIn or YouTube.